Business Description
Ascendis Pharma A/S
NAICS : 325411
SIC : 2833
ISIN : US04351P1012
Share Class Description:
ASND: ADRCompare
Compare
Traded in other countries / regions
ASND.USAA71.GermanyA1SN34.BrazilASND.Mexico IPO Date
2015-01-28Description
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.85 | |||||
| Equity-to-Asset | 0.08 | |||||
| Debt-to-Equity | 7.8 | |||||
| Debt-to-EBITDA | -1.04 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 2.67 | |||||
| Beneish M-Score | 0.38 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 44.6 | |||||
| 3-Year EBITDA Growth Rate | -24.5 | |||||
| 3-Year EPS without NRI Growth Rate | -28.3 | |||||
| 3-Year FCF Growth Rate | -30.6 | |||||
| 3-Year Book Growth Rate | -29.3 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 11.51 | |||||
| 9-Day RSI | 23.93 | |||||
| 14-Day RSI | 33.28 | |||||
| 6-1 Month Momentum % | 34.93 | |||||
| 12-1 Month Momentum % | -1.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.52 | |||||
| Quick Ratio | 2.65 | |||||
| Cash Ratio | 2.24 | |||||
| Days Inventory | 1939.1 | |||||
| Days Sales Outstanding | 36.29 | |||||
| Days Payable | 1526.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6 | |||||
| Shareholder Yield % | -4.35 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.44 | |||||
| Operating Margin % | -477.99 | |||||
| Net Margin % | -503 | |||||
| ROE % | -196.96 | |||||
| ROA % | -55.47 | |||||
| ROIC % | -220.55 | |||||
| ROC (Joel Greenblatt) % | -308.1 | |||||
| ROCE % | -56.09 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 38.91 | |||||
| PB Ratio | 70.33 | |||||
| Price-to-Tangible-Book | 75.74 | |||||
| EV-to-EBIT | -9.38 | |||||
| EV-to-Forward-EBIT | -9.65 | |||||
| EV-to-EBITDA | -9.72 | |||||
| EV-to-Forward-EBITDA | -10.16 | |||||
| EV-to-Revenue | 40.52 | |||||
| EV-to-Forward-Revenue | 15.62 | |||||
| EV-to-FCF | -9.22 | |||||
| Earnings Yield (Greenblatt) % | -10.66 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ASND
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ascendis Pharma A/S Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 126.703 | ||
| EPS (TTM) ($) | -11.379 | ||
| Beta | 0.14 | ||
| Volatility % | 50.93 | ||
| 14-Day RSI | 33.28 | ||
| 14-Day ATR ($) | 3.848871 | ||
| 20-Day SMA ($) | 97.55675 | ||
| 12-1 Month Momentum % | -1.16 | ||
| 52-Week Range ($) | 64.33 - 134.525 | ||
| Shares Outstanding (Mil) | 56.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ascendis Pharma A/S Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ascendis Pharma A/S Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ascendis Pharma A/S Frequently Asked Questions
What is Ascendis Pharma A/S(ASND)'s stock price today?
The current price of ASND is $87.86. The 52 week high of ASND is $134.53 and 52 week low is $64.33.
When is next earnings date of Ascendis Pharma A/S(ASND)?
The next earnings date of Ascendis Pharma A/S(ASND) is 2023-11-02 Est..
Does Ascendis Pharma A/S(ASND) pay dividends? If so, how much?
Ascendis Pharma A/S(ASND) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers